1 / 11

C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June

C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June. Trial Profile. C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June. Baseline demographic features and laboratory measurements by treatment allocation.

herbst
Télécharger la présentation

C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June

  2. Trial Profile C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June

  3. Baseline demographic features and laboratory measurements by treatment allocation C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June

  4. Average use of study simvastatin plus ezetimibe or non-study statin and average change in plasma LDL cholesterol from baseline, by period of follow-up C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June

  5. Life-table plot of effects of allocation to simvastatin plus ezetimibe versus placebo on major atherosclerotic events C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June

  6. Major atherosclerotic events subdivided by type C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June

  7. Major atherosclerotic events by baseline characteristics χ² tests on 1 degree of freedom are shown for heterogeneity between rate ratios within dichotomous categories and for trend within other categories. BP=blood pressure. MDRD=Modifi ed Diet in Renal Disease formula.17 GFR=glomerular fi ltration rate C. Baigent, et al. Lancet 2011;Epub 9 June

  8. Cause-specific and overall mortality C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June

  9. Cancer incidence and cancer mortality by site C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June

  10. Effects of allocation to simvastatin plus ezetimibe on muscle and hepatobiliary system C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June

  11. Effects of LDL-lowering therapy on particular vascular outcomes in four trials in patients with chronic kidney disease and 23 trials in other patients Data from the Cholesterol Treatment Trialists’ Collaboration. χ² tests are shown for eterogeneity between rate ratios for each outcome in the four trials (4D, ALERT, AURORA, and SHARP) in patients with chronic kidney disease. MI=myocardial infarction. LDL-C=LDL-cholesterol. C. Baigent, et al. Lancet 2011;Epub 9 June

More Related